Novartis nabs cardio drug with $1.4bn Tourmaline buy Novartis has beefed up its cardiology by agreeing a $1.4bn takeover of Tourmaline Bio and its drug for atherosclerotic cardiovascular disease (ASCVD).

#Novartis has bulked up its #cardiology pipeline with a $1.4 billion #takeover of #TourmalineBio and its phase 3-ready drug for atherosclerotic cardiovascular disease (ASCVD).

pharmaphorum.com/news/novarti...

Click Subscribe #TourmalineBio #Phase2Trial #Investing #StockMarket #ClinicalTrials

Inflammation plays a key role in atherosclerosis, and hs-CRP is the most reliable biomarker for cardiovascular risk. An analysis of NHANES data found that 52% of U.S. adults have elevated hs-CRP levels ≥2 mg/L. Are you testing for inflammation?

#PreventiveCardiology #CVDPrevention #TourmalineBio